We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+26.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$849M
AUM Growth
+$158M
(+23%)
Cap. Flow
+$88.5M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
48.96%
Holding
87
New
21
Increased
16
Reduced
27
Closed
18
Top Buys
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$25.5M |
| 2 |
Monte Rosa Therapeutics
GLUE
|
+$18.6M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$16.9M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$16.5M |
| 5 |
Immunome
IMNM
|
+$16.1M |
Top Sells
| 1 |
ABVX
Abivax
ABVX
|
+$14.2M |
| 2 |
CG Oncology
CGON
|
+$11M |
| 3 |
Viridian Therapeutics
VRDN
|
+$10.8M |
| 4 |
Pfizer
PFE
|
+$10.4M |
| 5 |
Avalo Therapeutics
AVTX
|
+$9.52M |
Sector Composition
| 1 | Healthcare | 98.55% |
| 2 | Financials | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Olema Pharmaceuticals
OLMA
$1.04B
| – | – |
-206,280
| Closed | -$5.16M |
|
77
Palisade Bio
PALI
$335M
| – | – |
-102,108
| Closed | -$240K |
|
|
78
Pfizer
PFE
$138B
| – | – |
-419,134
| Closed | -$10.4M |
|
79
uniQure
QURE
$2.85B
| – | – |
-126,047
| Closed | -$2.55M |
|
80
Ultragenyx Pharmaceutical
RARE
$3.15B
| – | – |
0
| – | – |
|
81
Relay Therapeutics
RLAY
$4.16B
| – | – |
-398,167
| Closed | -$3.37M |
|
|
SLNO
82
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-117,485
| Closed | -$5.44M |
|
83
Tarsus Pharmaceuticals
TARS
$2.45B
| – | – |
-36,124
| Closed | -$2.96M |
|
|
84
Viridian Therapeutics
VRDN
$2.11B
| – | – |
-348,569
| Closed | -$10.8M |
|
85
X4 Pharmaceuticals
XFOR
$379M
| – | – |
-357,387
| Closed | -$1.43M |
|
86
State Street SPDR NYSE Technology ETF
XNTK
$2.18B
| – | – |
0
| – | – |
|
|
RAPP
87
Rapport Therapeutics
RAPP
$1.98B
| – | – |
-9,659
| Closed | -$293K |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA